Group 1 - The core point of the article is that 惠陶集团 (Huitao Group) is planning to issue up to 17.416 million shares at a price of HKD 0.34, which represents a discount of approximately 20% compared to the closing price of HKD 0.425 on October 15 [1] - The total estimated gross proceeds from the placement will be around HKD 5.92 million, with a net amount of approximately HKD 5.4 million intended for current business operations and general working capital [1] - On October 17, shareholders transferred shares from 宏智证券 (Hongzhi Securities) to 致富证券 (Zhifu Securities), with a market value of HKD 2.6401 million, accounting for 6.19% of the total shares [1]

Core Viewpoint - InnoCare Pharma (02577.HK) has successfully completed a placement of 20.7 million new H-shares at a price of HKD 75.58 per share, raising approximately HKD 1.5504 billion, which will enhance the company's financial strength and market competitiveness [1] Group 1 - The placement agreement conditions have been fully met, and the placement was completed on October 17, 2025 [1] - A total of 20.7 million new H-shares were issued, representing about 3.94% of the total issued H-shares and approximately 2.26% of the total issued shares after the placement [1] - The net proceeds from the placement are approximately HKD 1.5504 billion, which will further strengthen the group's financial position and support its long-term sustainable development [1]

Core Viewpoint - The company, Zhengli New Energy, has entered into a placement agreement to issue 45.921 million new H-shares at a price of HKD 10.98 per share, which represents a discount to the market price, aimed at enhancing its financial strength and supporting future growth initiatives [1][2]. Group 1 - The placement shares represent approximately 3.19% of the issued H-shares as of the announcement date and about 1.83% of the total issued shares [1]. - The placement price of HKD 10.98 per share is approximately 7.89% lower than the closing price of HKD 11.92 on the trading day prior to the agreement [1]. - The total proceeds from the placement, assuming full subscription, will amount to HKD 504 million, with a net amount estimated at HKD 500.4 million [2]. Group 2 - Approximately 70% of the net proceeds will be allocated to support the construction, equipment purchase, and preparatory expenses related to the second phase of the new production facility in Changshu [2]. - About 10% of the net proceeds will be used for the construction of a pilot line for all-solid-state batteries [2]. - The remaining 10% of the net proceeds will be allocated for research and development activities, as well as working capital and general corporate purposes [2].

Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定者外，本公告所用詞彙與博泰車聯網科技（上海）股份有限公司（「本公司」） 日期為2025年9月22日的香港招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 有意投資者於決定是否投資於發售股份前，務請細閱招股章程中有關下文所述全球發售的詳細 資料。任何有關發售股份的投資決定應僅依據招股章程所提供的資料作出。 本公告不得直接或間接於或向美國境內（包括其領土及屬地、美國任何州及哥倫比亞特區）發 佈、刊發、分發。本公告並不構成或組成於美國或任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。本公告所述證券並無亦不會根據《1933年美國證券法》（經不時修訂） （「美國證券法」）或美國任何州或其他司法管轄區的證券法登記。除非進行獲豁免遵守美國證券 法的登記規定或 ...

Core Insights - The Hong Kong Stock Exchange reported that on September 22, Dragon Resources (01712) shareholders deposited stocks into Wanji Securities, with a market value of HKD 227 million, accounting for 20% [1] Company Summary - Dragon Resources announced that all conditions for the placement matter have been fulfilled, and the transaction was completed on September 22, 2025 [1] - A total of 31.6193 million shares were successfully placed by the placement agent at a price of HKD 5.61 per share, with at least six subscribers participating [1] - The 31.6193 million shares represent 20.0% of the company's total issued shares prior to completion and approximately 16.67% of the expanded total issued shares after the placement [1] - No subscriber became a major shareholder after the completion of the placement [1]

Group 1 - The core point of the article is that Ying Sheng Science (00209) has completed a placement agreement, issuing a total of 30.95 million shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's expanded issued share capital as of the announcement date [1][1][1] - On September 19, shareholders deposited shares into Imagi Brokerage Limited, with a market value of HKD 8.9759 million, accounting for 20% [1][1][1] - All conditions outlined in the placement agreement have been met, and the placement was completed according to the terms and conditions of the agreement [1][1][1]

Core Viewpoint - The recent stock transfer and placement agreement of Ying Sheng Science indicates significant financial activities and capital restructuring within the company, highlighting its strategic focus on debt repayment and operational funding [1] Group 1: Stock Transfer - On September 16, shareholders of Ying Sheng Science transferred shares from Hope Securities to Bank of China (Hong Kong), with a market value of HKD 3.7261 million, accounting for 8.45% of the total shares [1] Group 2: Placement Agreement - On September 11, Ying Sheng Science announced a placement agreement with a placement agent, agreeing to place 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the enlarged issued share capital post-placement [1] - The total nominal value of the placement shares will be HKD 309,500 [1] - The total proceeds from the placement are estimated to be HKD 10.833 million, with a net amount of approximately HKD 10.32 million after deducting all related expenses [1] Group 3: Use of Proceeds - Approximately 50% of the net proceeds from the placement is intended for loan repayment, while the other 50% is earmarked for the group's working capital and general corporate purposes [1]

公司已于2025年9月2日以每股H股29.28港元的配售价成功向不少于6名承配人(为独立专业或机构投资 者)配发及发行合共4002.56万股新H股，相当于经配售及已发行配售股份扩大后已发行H股数目的 9.02%。 9月2日，赣锋锂业发布公告，公司配售协议中载列的所有配售先决条件已获满足(包括获得上市批准)， 配售于2025年9月2日完成。 香港联交所最新资料显示，9月4日，赣锋锂业（002460）(01772)股东将股票由法国巴黎银行转入花旗 银行，转仓市值5.25亿港元，占比3.89%。 ...

Core Viewpoint - Shandong Gold announced a placement agreement to issue up to 136.5 million H-shares at a price of HKD 28.58 per share, aiming to raise approximately HKD 3.89242 billion for debt repayment [1] Group 1 - The placement is scheduled to be completed on September 2, 2025, before the trading session on the Hong Kong Stock Exchange [1] - The net proceeds from the placement are expected to be approximately HKD 3.89242 billion, assuming all shares are successfully placed [1] - The funds raised will primarily be used to repay the company's debts [1]